We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01061437
Recruitment Status : Completed
First Posted : February 3, 2010
Last Update Posted : September 26, 2012
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to compare the effectiveness of three different antibiotic regimens against Helicobacter pylori (H. pylori).

Condition or disease Intervention/treatment Phase
Helicobacter Pylori Infection Drug: PACx14 Drug: PACMx5 Drug: PAx5/PCMx5 Phase 3

Detailed Description:
Prevention of gastric cancer through eradication of H. pylori is one of the most promising strategies to reduce the global impact of cancer in the near term. Our long-term goal is to prevent gastric cancer by developing and validating an effective, simple, and low-cost approach to eradication of H. pylori. Our immediate goal, therefore, is to conduct a randomized study to compare the effectiveness of three different drug regimens for H. pylori infection. The three study arms are: Standard therapy - 14 day, 3-drug regimen of Lansoprazole, amoxicillin and clarithromycin (PACx14); Concomitant therapy - 5 day, 4-drug regimen of lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5); Sequential therapy - 10 day, 4-drug regimen of lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5).

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1859 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori
Study Start Date : June 2009
Primary Completion Date : July 2011
Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antibiotics
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: Arm 1
Standard 14 day, 3-drug regimen
Drug: PACx14
Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)
Other Name: Lansoprazole: Prevacid
Experimental: Arm 2
Concomitant Therapy - 5 day, 4-drug regimen
Drug: PACMx5
Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)
Other Name: Lansoprazole: Prevacid
Experimental: Arm 3
Sequential Therapy - 10 day, 4-drug regimen
Drug: PAx5/PCMx5
Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
Other Name: Lansoprazole: Prevacid


Outcome Measures

Primary Outcome Measures :
  1. To compare 2 experimental antibiotic regimens with a standard 14 day regimen with regard to H. pylori eradication rates at 6 weeks post-randomization. [ Time Frame: week 6 post-randomization ]

Secondary Outcome Measures :
  1. Secondary aims will examine infection rates at 1 year, safety and tolerability of these regimens,& potential differential effects among selected groups. [ Time Frame: 1 year ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • positive Urea Breath Test documenting H. pylori infection
  • age 21 - 65 years
  • no known allergies to study drugs
  • only member of household participating in study
  • no known medical conditions (other than H. pylori) that would preclude or require antibiotic therapy
  • patients must be willing to discontinue alcohol use for 15 days (maximum duration of treatment plus one day)
  • patients must be willing to discontinue use of antacids for duration of study treatment
  • patients must not have used proton pump inhibitors (PPI) within 30 days of registration. Patients also must be willing to stop using non-study provided PPIs until the completion of the 6 week follow-up contact.
  • patients must not have been treated with antibiotics for H. pylori in the past and must not have taken any other antibiotics within 30 days of registration.
  • patients must be willing to return for 2 follow-up visits: 6 weeks after randomization following completion of treatment & 1 year after randomization
  • patients must be willing to allow submission of blood for assays of serum markers of bacterial virulence and host genetic susceptibility and environmental factors and provide consent for use of specimens.

Exclusion Criteria:

  • current use of anti-retroviral therapy for HIV or AIDS
  • diagnosed congestive hear failure
  • renal failure requiring dialysis
  • diagnosed hepatic failure resulting in hyperbilirubinemia
  • any current or prior malignancy except: adequately treated basal or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or Stage II cancer from which the patient has been disease free for 5 years
  • pregnancy or nursing mothers
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01061437


Locations
Chile
Pontificia Universidad Catolica de Chile
Santiago, Chile
Colombia
Universidad del Valle
Cali, Valle, Colombia
Costa Rica
Fundacion Inciensa
San Jose, Costa Rica
Honduras
Hospital Occidente
Copan, Honduras
Mexico
National Institute for Public Health
Cuernavaca, Morelos, Mexico
Instituto Technologico de Sonora
Obregon, Sonora, Mexico
Nicaragua
Centro de Investigacion en Demografia y Salud de la Iglesia Merced
Leon, Nicaragua
Sponsors and Collaborators
Southwest Oncology Group
Bill and Melinda Gates Foundation
Investigators
Principal Investigator: E. Robert Greenberg, M.D. Southwest Oncology Group
More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Southwest Oncology Group
ClinicalTrials.gov Identifier: NCT01061437     History of Changes
Other Study ID Numbers: S0701
First Posted: February 3, 2010    Key Record Dates
Last Update Posted: September 26, 2012
Last Verified: September 2012

Keywords provided by Southwest Oncology Group:
H. pylori

Additional relevant MeSH terms:
Helicobacter Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Anti-Bacterial Agents
Lansoprazole
Dexlansoprazole
Anti-Infective Agents
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action